De Maeyer Joris H, Prins Nicolaas H, Schuurkes Jan A J, Lefebvre Romain A
Heymans Institute of Pharmacology, De Pintelaan 185, 9000 Gent, Belgium.
J Pharmacol Exp Ther. 2006 Jun;317(3):955-64. doi: 10.1124/jpet.106.101329. Epub 2006 Feb 24.
Quantification of different levels of 5-hydroxytryptamine4 (5-HT4) receptor agonism expression across animal species as well as across organs within the same animal species offers substantial potential for the separation of desired gastrointestinal versus undesired cardiac pharmacological activity of compounds in development. Since a detailed investigation of such properties is lacking to date, we set out to quantify gastric and cardiac effects of 5-HT4 receptor ligands in the pig, a model considered to be representative for the human situation. An in vitro test was developed to study the potentiating effect of 5-HT, prucalopride, tegaserod, R149402 (4-amino-5-chloro-2,2-dimethyl-2,3-dihydro-benzofuran-7-carboxylic acid [3-hydroxy-1-(3-methoxy-propyl)-piperidin-4ylmethyl]-amide), and R199715 (4-amino-5-chloro-2,3-dihydro-benzofuran-7-carboxylic acid [3-hydroxy-1-(3-methoxy-propyl)-piperidin-4ylmethyl]-amide) on electrically induced cholinergic contractions in longitudinal muscle strips of the proximal stomach. The results were compared with inotropic and chronotropic effects of these compounds in the electrically paced left atrium and spontaneously beating right atrium, respectively. To quantify the observed tissue-dependent responses, a nonlinear mixed-effects model based on the operational model of agonism was developed and successfully fitted to the data. The model quantified the tissue-dependent partial agonism of the selective 5-HT4 receptor agonists prucalopride, R149402, and R199715, whereas tegaserod and 5-HT were equiefficacious. The model was further extended to incorporate the responses to prucalopride in the presence of the 5-HT4 receptor antagonist GR113808 ([1-[2-[(methylsulphonyl)amino]ethyl]-4-piperidinyl-]methyl 1-methyl-1H-indole-3-carboxylate). The results indicate that these interactions do not follow a simple competitive pattern and that they differ between stomach and left atrium.
量化不同动物物种以及同一动物物种不同器官中5-羟色胺4(5-HT4)受体激动作用的不同水平,对于区分处于研发阶段化合物所需的胃肠道药理活性和不需要的心脏药理活性具有巨大潜力。由于迄今为止缺乏对此类特性的详细研究,我们着手量化5-HT4受体配体对猪的胃和心脏的影响,猪被认为是人类情况的代表性模型。我们开发了一种体外试验,以研究5-羟色胺、普芦卡必利、替加色罗、R149402(4-氨基-5-氯-2,2-二甲基-2,3-二氢苯并呋喃-7-羧酸[3-羟基-1-(3-甲氧基丙基)-哌啶-4-基甲基]酰胺)和R199715(4-氨基-5-氯-2,3-二氢苯并呋喃-7-羧酸[3-羟基-1-(3-甲氧基丙基)-哌啶-4-基甲基]酰胺)对胃近端纵肌条电诱导胆碱能收缩的增强作用。分别将这些结果与这些化合物对电起搏左心房和自主跳动右心房的变力和变时作用进行比较。为了量化观察到的组织依赖性反应,我们基于激动作用的操作模型开发了一个非线性混合效应模型,并成功地将其拟合到数据中。该模型量化了选择性5-HT4受体激动剂普芦卡必利、R149402和R199715的组织依赖性部分激动作用,而替加色罗和5-羟色胺具有同等效力。该模型进一步扩展,以纳入5-HT4受体拮抗剂GR113808([1-[2-[(甲基磺酰基)氨基]乙基]-4-哌啶基]甲基1-甲基-1H-吲哚-3-羧酸酯)存在时对普芦卡必利的反应。结果表明,这些相互作用并不遵循简单的竞争模式,并且在胃和左心房之间存在差异。